S10.9 · Food, Agriculture & Beverage
Bulk milling and crushing at commodity margins sit alongside specialty ingredients at much higher margins, with AI compressing formulation R&D cycles.
No single figure spans both ends of this segment, and the reason is the point. Bulk primary processing — milling, crushing, refining — is priced off commodity spreads, and its revenue folds into the scale of the major grain traders that run it; the specialty and functional ingredients sub-segment alone is estimated at roughly $180-200B (2024, Grand View Research/MarketsandMarkets, 2025). Bulk runs on throughput at low-single-digit margins. Formulated specialty ingredients run mid-teens-plus margins on intellectual property and customer switching costs. The gap between those two halves is the whole story here, and AI is now compressing the R&D cycle time that has historically protected the specialty half.
Bulk processing volume tracks crop volumes — essentially flat-to-low-growth — while specialty ingredients (proteins, fibers, flavors, enzymes) grow mid-to-high single digits on clean-label and functional-food demand. Geography follows the economics: bulk processing co-locates with grain origination in the US, Brazil and the EU; specialty-ingredient R&D concentrates in the US, the Netherlands, Denmark and Switzerland. ADM, Cargill, Bunge and Ingredion dominate bulk processing; specialty ingredients are more fragmented, spread across companies including Kerry, IFF, Tate & Lyle and Ingredion's own specialty operations.
The segment sits downstream of grain and oilseed trading and upstream of branded food and beverage manufacturers. The gap between the two halves is structural, not cyclical. Bulk milling and crushing compete on throughput and logistics efficiency, with margins set by commodity spreads no single processor controls. Specialty ingredients compete on formulation know-how and on the switching cost a customer takes on when reformulating a product around a supplier's ingredient — a genuinely different business housed under the same segment label.
The strategic motion inside this segment is mix shift: processors moving revenue from bulk toward specialty, trading throughput-driven margin for formulation-driven margin. ADM's push into nutrition and Ingredion's build-out of its specialty ingredient lines are the visible versions of the move. A further set of adjacencies — alternative-protein ingredient supply, flavor and fragrance, precision fermentation — extends the specialty side into still higher-margin, more differentiated territory.
AI's effect lands on the specialty half of the business, where AI-driven ingredient and recipe screening is collapsing formulation R&D cycle time — software iterating through candidate formulations far faster than a bench chemist working through combinations by hand. The exposed party is the legacy formulation lab that has competed on chemist headcount rather than platform speed: a smaller, AI-equipped formulation team now covers ground that used to require a much larger lab. This is already underway inside the innovation centers of the major ingredient houses. The dynamic is competitive and present, not prospective.